NanosVet sells $8.3M to build fast-dissolving pet medicine

Why it matters

The $8.3M gives Andrew Green room to turn one pet-wellness strip into a veterinary drug-delivery platform. Clinical evidence and repeatable manufacturing will determine whether NanoMelt earns that label.

Andrew Green, founder and CEO of NanosVet, has sold $8.3 million of securities to finance a pet-health platform built around fast-dissolving oral strips, according to a Form D filed with the SEC.

The Los Angeles-based NanosVet began selling the securities on September 15th. The filing, signed by Green on September 17th and posted by the SEC on September 18th, sets the total offering at $8,623,920. That leaves $323,920 unsold. The offering includes $123,920 tied to warrants.

Green started NanosVet after his dog nearly died from anaphylaxis, according to NanosVet's account of its founding. The emergency left him focused on a basic problem in veterinary care: pet owners can administer some routine treatments at home, yet fast intervention often still requires a pill an animal may reject or an injection delivered at a clinic.

His proposed answer is NanoMelt, a thin film designed to adhere inside an animal's mouth and carry active ingredients across the oral mucosa. The format is intended to make dosing easier while avoiding the digestive pathway used by conventional tablets.

A round sized for the hard part

The offering notice lists 17 investors and uses the SEC's Rule 506(b) exemption. NanosVet reported no sales commissions or finder fees. Green is listed as an executive officer and director, David Rosenblatt as an executive officer and director, and Ben Bryce as a director.

The filing does not identify the investors or assign NanosVet a valuation. Veterinary Angel Network, or VANE, announced an investment in May when it named NanosVet its 38th portfolio company. NanosVet also joined Leap Venture Studio's 2026 cohort, an accelerator backed by Mars Petcare, Michelson Found Animals Foundation and TAW Ventures. The program provides $200,000 to each core cohort member, though the available records do not establish whether that capital sits inside the $8.3 million reported to the SEC.

The size of Green's financing stands out against what NanosVet has put on sale so far. NanosVet currently lists a Fresh Breath dental strip starting at $19.99. Calm +, Soothe & Move and Itch Ease remain marked as coming soon.

That gap puts the round's purpose into focus. Green is funding the transition from a single consumer wellness product to a delivery platform capable of supporting supplements, personalized doses and eventually prescription medicines. The technical and regulatory burden rises sharply with that ambition.

Green is selling a delivery system, not a strip

NanosVet says its strips dissolve in under 30 seconds and advertises absorption that is up to seven times faster. The technical explanation published by NanosVet says active molecules pass through oral mucosal tissue into systemic circulation, reducing exposure to stomach acids and first-pass liver metabolism.

Those claims remain NanosVet's claims. NanosVet has not published molecule-specific pharmacokinetic or clinical results supporting the advertised absorption figure. That evidence will matter because an oral film's performance depends on the active ingredient, dose, formulation, animal species and intended use. A dental supplement cannot validate a future emergency medicine or chronic-care drug.

Green has still earned early recognition inside animal health. NanosVet won the nutrition category at the 2026 AHNTI EU Innovation Showcase, where Green presented as founder and CEO. VANE's backing and the Leap selection add industry relationships that could help NanosVet reach veterinary practices, pharmaceutical partners and regulatory specialists.

The financing gives Green considerably more room to build than the usual pet-wellness launch. It also gives NanosVet a higher standard to meet. NanosVet calls its products pharmaceutical-grade and traces NanoMelt to human drug-delivery methods. Turning that language into a defensible platform will require consistent manufacturing, stability work, dosing studies and safety and effectiveness data for each therapeutic application.

The FDA's animal-drug approval process evaluates safety, effectiveness, manufacturing and labeling. Prescription products also require veterinary oversight. NanosVet's plan to pair personalized fulfillment with televet support therefore adds a service and compliance layer alongside the formulation work.

Oral film is already a category

Green is entering a market with existing oral-film developers and pet-strip brands. Nualtis lists veterinary oral-film programs for pain, behavioral health and chronic care, including a buprenorphine program. PetPax sells fast-dissolving supplement films for calming and dental health. Oak Therapeutics says its broader oral-strip platform can carry more than 350 milligrams of active ingredients and tune dissolution from seconds to hours.

That competitive set prevents NanosVet from relying on the format alone. Green's differentiation rests on combining rapid dissolution with customized dosing, pharmaceutical development and a consumer-friendly fulfillment channel. Each part adds potential value, and each part adds execution risk.

The $8.3 million disclosure suggests investors are underwriting the broader platform before NanosVet has publicly demonstrated it across a large catalog. Green now has the capital to produce the evidence that separates a useful delivery technology from a well-packaged pet supplement.

For pet owners, the appeal is easy to understand. Pills hidden in food get found, spat out or swallowed inconsistently. A strip that reliably delivers the intended dose would solve a daily problem for owners, veterinarians and animals. Green's task is to prove that NanoMelt can provide that reliability when the active ingredient matters as much as the convenience.